ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

L.I. Center At Stony Brook’s Goal Is Comprehensive Status.

October 27, 2000

Regulations Threaten Clinical Trials Higgins contends

May 16, 1980

BMI May Be Prognostic Tool For Types Of Breast Cancer

March 28, 2008

In Brief: Use More Ad Hoc Committees For Grants, Look At Number, Distribution Of Centeres: Katterhagen

August 28, 1981

NCI’s Oral Cancer Chemoprevention Trial On Hold After Fraud Allegations In Norway.

January 27, 2006

In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center

June 20, 2014